

CORRECTION

Open Access

Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis

Jessica M Nielsen^{1*}, Christoph Pohl², Chris H Polman¹, Frederik Barkhof³, Mark S Freedman⁴, Gilles Edan⁵, David H Miller⁶, Lars Bauer², Rupert Sandbrink², Ludwig Kappos⁷, Bernard MJ Uitdehaag^{1,8}

In our article [1], we did not declare some potential competing interests for Prof. Dr. med. Ludwig Kappos:

Declaration of competing interests:

Prof. Dr. med. Ludwig Kappos

LK has participated in the last 24 months as principal investigator, member or chair of planning and steering committees or advisory boards in corporate-sponsored clinical trials in multiple sclerosis and other neurological diseases. The sponsoring pharmaceutical companies for these trials include Actelion, Advancell, Allozyne, BaroFold, Bayer Health Care Pharmaceuticals, Bayer Schering Pharma, Bayhill, Biogen Idec, BioMarin, CLC Behring, Elan, Genmab, GeNeuro SA, Genmark, GlaxoSmithKline, Lilly, Merck Serono, MediciNova, Novartis, Novonordisk, Peptimmune, sanofi-aventis, Santhera, Roche, Teva, UCB and Wyeth.

I have also lectured at medical conferences or in public on various aspects of the diagnosis and management of multiple sclerosis. In many cases these talks have been sponsored by non-restricted educational grants from one or another of the above listed companies.

Honoraria and other payments for all these activities have been exclusively used for funding of research of my department.

Research and the clinical operations (nursing and patient care services) of the MS Center in Basel have been supported by non-restricted grants from one or more of these companies and by grants from the Swiss MS Society, the Swiss National Research Foundation, the European Union, the Gianni Rubatto, Novartis and Roche Research Foundations.

* Correspondence: jm.nielsen@vumc.nl

¹MS Center, Department of Neurology, VU Medical Center, Amsterdam, The Netherlands

Full list of author information is available at the end of the article

Author details

¹MS Center, Department of Neurology, VU Medical Center, Amsterdam, The Netherlands. ²Bayer Schering AG, Berlin, Germany. ³Department of Radiology, VU medical Center, Amsterdam, The Netherlands. ⁴Department of Neurology, The Ottawa Hospital, Ontario, Canada. ⁵Department of Neurology, Hôpital Pontchaillou, Rennes, France. ⁶Department of Radiology, Queen square hospital, London, UK. ⁷Department of Neurology, Kantonsspital, Basel, Switzerland. ⁸Department of Epidemiology and Biostatistics, VU Medical Center, Amsterdam, The Netherlands.

Received: 4 February 2011 Accepted: 4 February 2011

Published: 4 February 2011

Reference

1. Nielsen M, Pohl C, Polman H, Barkhof F, Freedman S, Edan G, Miller H, Bauer L, Sandbrink R, Kappos L, Uitdehaag M, Bernard B: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis. *BMC Neurology* 2009, **9**:19.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2377/11/19/prepub>

doi:10.1186/1471-2377-11-19

Cite this article as: Nielsen et al.: Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis. *BMC Neurology* 2011 **11**:19.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

